The Macdonald-Laurier Institute has released a series of three papers, in the Defending our Rights series, which details how Canada can become a global intellectual property leader.
Trade and Intellectual Property
The MacDonald-Laurier Institute's Richard Owens writes that a ruling in Access Copyright v. York University issued by Judge Phelan of the Federal Court of Canada represented a significant victory for Canadian content creators.
The Macdonald-Laurier Institute's Richard Owens writes that Canada's effective decision to reverse the so-called promise doctrine, a more expansive test of patent utility, is an important step forward for Canadian patent law.
This report is the first in a series of three that will examine the importance of stronger intellectual property rights (IPRs) to Canada's economy.
MLI argues that Canadian innovation will be harmed if Canada's federal government continues to ignore the intellectual problems the "promise doctrine" creates.
This C. D. Howe Institute report assesses the claims that strengthened protection for pharmaceutical patents pursuant to the terms of the the Comprehensive Economic and Trade Agreement (CETA) between Canada and the European Union and the TPP would result in an increase in health care costs and provide some estimates of C. D. Howe's own on the issue.
MLI writes that the United Nations High-Level Report on Access to Medicines, which calls for loosening intellectual property regulations (ostensibly to make drugs cheaper) would only make it more difficult to provide drug access to the world's most impoverished.
This MLI study explores the many copyright issues facing the Canadian Heritage minister, and shows that supporting Canada’s artists, musicians and authors is about more than government programs and subsidies.
Fundación IDEA writes about the importance of intellectual property as a driver of innovation and competitiveness in Mexico.
To ensure the Trans-Pacific Partnership (TPP) Agreement creates a framework in which life sciences innovation flourishes throughout the TPP region, it needs to include 12 years of data protection for novel biologic drugs.